Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations.
about
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations.
@en
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations.
@nl
type
label
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations.
@en
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations.
@nl
prefLabel
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations.
@en
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations.
@nl
P2093
P2860
P50
P1433
P1476
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
@en
P2093
Giulia Fornasier
Paolo Baldo
Sara Francescon
P2860
P2888
P304
P356
10.1007/S40487-016-0028-9
P577
2016-08-11T00:00:00Z